Virginia PiÃ±ol

List of Publications by Year
in descending order

40 papers	2,709 citations	257450 24 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	3368 citing authors

#	Article	IF	Citations
1	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
2	Potential Involvement of NSD1, KRT24 and ACACA in the Genetic Predisposition to Colorectal Cancer. Cancers, 2022, 14, 699.	3.7	0
3	A case report of gastrointestinal histoplasmosis in a patient treated with infliximab. Clinical Journal of Gastroenterology, 2021, 14, 690-692.	0.8	4
4	Non-Lynch Familial and Early-Onset Colorectal Cancer Explained by Accumulation of Low-Risk Genetic Variants. Cancers, 2021, 13, 3857.	3.7	8
5	Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. Diagnostics, 2020, 10, 1036.	2.6	1
6	New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population. PLoS ONE, 2020, 15, e0243158.	2.5	14
7	Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test. World Journal of Gastroenterology, 2020, 26, 70-85.	3.3	8
8	High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy, 2019, 51, 142-151.	1.8	26
9	NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas. Scientific Reports, 2019, 9, 9020.	3.3	23
10	Reduction of faecal immunochemical test falseâ€positive results using a signature based on faecal bacterial markers. Alimentary Pharmacology and Therapeutics, 2019, 49, 1410-1420.	3.7	12
11	Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. Clinical Epigenetics, 2019, 11, 171.	4.1	7
12	Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut, 2018, 67, 2230-2232.	12.1	48
13	Sa1253 VERRUCOUS GASTRITIS MIGHT BE A RISK FACTOR FOR EARLY GASTRIC NEOPLASIA IN THE WEST. Gastrointestinal Endoscopy, 2018, 87, AB183.	1.0	3
14	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. International Journal of Cancer, 2017, 140, 2201-2211.	5.1	61
15	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology, 2017, 153, 106-112.e2.	1.3	28
16	Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine, 2016, 14, 128.	5.5	56
17	Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut, 2016, 65, 1829-1837.	12.1	93
18	POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genetics in Medicine, 2016, 18, 325-332.	2.4	209

#	Article	IF	Citations
19	Endoscopic surveillance in patients with multiple (10â€“100) colorectal polyps. Endoscopy, 2015, 48, 56-61.	1.8	1
20	Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut, 2012, 61, 865-872.	12.1	172
21	Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut, 2007, 56, 1714-1718.	12.1	85
22	Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repairâ€Deficient Colorectal Tumors. Journal of the National Cancer Institute, 2007, 99, 244-252.	6.3	157
23	Detection of Metachronous Neoplasms in Colorectal Cancer Patients: Identification of Risk Factors. Diseases of the Colon and Rectum, 2007, 50, 971-980.	1.3	64
24	Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial. Journal of Clinical Oncology, 2006, 24, 386-393.	1.6	259
25	Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair Deficiency. Clinical Cancer Research, 2006, 12, 1686-1692.	7.0	35
26	Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations. American Journal of Gastroenterology, 2006, 101, 1104-1111.	0.4	36
27	Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut, 2006, 55, 848-855.	12.1	199
28	Late-Occurring Liver Metastases in Colorectal Cancer. Digestive Diseases and Sciences, 2005, 50, 345-347.	2.3	2
29	Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator Pathway. Clinical Cancer Research, 2005, 11, 7304-7310.	7.0	119
30	Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 1986.	7.4	457
31	Genomic rearrangements in and are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. Cancer Letters, 2005, 225, 93-98.	7.2	17
32	Synchronous Colorectal Neoplasms in Patients With Colorectal Cancer: Predisposing Individual and Familial Factors. Diseases of the Colon and Rectum, 2004, 47, 1192-1200.	1.3	55
33	Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. European Journal of Gastroenterology and Hepatology, 2004, 16, 39-45.	1.6	72
34	Utilidad de la colonografÃa por tomografÃa computarizada en la detecciÃ³n de pÃ³lipos colorrectales. Medicina ClÃnica, 2004, 123, 41-44.	0.6	3
35	Evaluation of PARVG located on 22q13 as a candidate tumor suppressor gene for colorectal and breast cancer. Cancer Genetics and Cytogenetics, 2003, 144, 80-82.	1.0	15
36	Prognostic Value of Postoperative Detection of Blood Circulating Tumor Cells in Patients With Colorectal Cancer Operated on For Cure. Annals of Surgery, 2003, 237, 368-375.	4.2	41

#	Article	IF	Citations
37	Title is missing!. Annals of Surgery, 2003, 237, 368-375.	4.2	29
38	Percutaneous Self-expanding Metal Stents versus Endoscopic Polyethylene Endoprostheses for Treating Malignant Biliary Obstruction: Randomized Clinical Trial. Radiology, 2002, 225, 27-34.	7.3	147
39	Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology, 2001, 120, 1084-1092.	1.3	70
40	Laparoscopic-assisted vs. open colectomy for colorectal cancer: influence on neoplastic cell mobilization,. Journal of Gastrointestinal Surgery, 2001, 5, 66-73.	1.7	35